New drug combo aims to tame Hard-to-Treat transplant complication
NCT ID NCT06233110
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether adding fostamatinib to the standard drug ruxolitinib can safely help people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a serious complication after a stem cell transplant where the donor cells attack the patient's body. The study will enroll about 30 adults and aims to find the best dose of fostamatinib to use with ruxolitinib, while also checking if the combination improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib and fostamatinib
What this could lead to
If successful, this combination could offer a new treatment option for people with chronic graft-versus-host disease that does not respond to steroids.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet known. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke
RECRUITINGDurham, North Carolina, 27710, United States
Contact